Idiopathic hypereosinophilic syndrome (IHES) is a disease that is difficult to classify, and diagnosis is one of exclusion. The identification of a cytogenetically invisible interstitial deletion resulting in the fusion of FIP1-Like-1 (FIP1L1) to platelet-derived growth factor receptor alpha (PDGFRA) has enabled many IHES cases to be reclassified as chronic eosinophilic leukemia. As it is likely that PDGFRA may fuse to other partner genes, we established a reverse transcriptase-PCR test to detect specific overexpression of the PDGFRA kinase domain as an indicator of the presence of a fusion gene. Overexpression was detected in 12/12 FIP1L1-PDGFRA-positive patients, plus 9/217 (4%) patients with hypereosinophilia who had tested negative for FIP1L1-PDGFRA. One of the positive cases was investigated in detail and found to have a complex karyotype involving chromosomes 3, 4 and 10. Amplification of the genomic breakpoint by bubble PCR revealed a novel fusion between KIF5B at 10p11 and PDGFRA at 4q12. Imatinib, a known inhibitor of PDGFRa, produced a complete cytogenetic response and disappearance of the KIF5B-PDGFRA fusion by PCR, from both genomic DNA and mRNA. This study demonstrates the utility of screening for PDGFRA kinase domain overexpression in patients with IHES and has identified a third PDGFRA fusion partner in chronic myeloproliferative disorders.
Introduction
Hypereosinophilic syndromes (HES) can arise from clonal disorders of the bone marrow, or from a number of reactive conditions. The diagnosis of idiopathic HES (IHES) is one of exclusion and the disease is characterized as a persistent state of unexplained eosinophilia for longer than 6 months, with evidence of organ dysfunction due to eosinophilic tissue infiltration and the consequent release of their granules and toxic contents. 1 If clonal proliferation of eosinophils can be demonstrated, then the disease should be reclassified as chronic eosinophilic leukemia (CEL) and treated accordingly. 2, 3 Although eosinophil clonality may be established for female subjects by X-inactivation assays, 4 in practice, it is usually only inferred from the finding of an acquired clonal cytogenetic abnormality in the bone marrow.
The diagnosis of CEL was revolutionized by the finding of an interstitial deletion on chromosome 4q12 that fuses the FIP1-Like-1 gene (FIP1L1) to the platelet-derived growth factor receptor alpha gene (PDGFRA). 5, 6 Importantly, the small molecule inhibitor imatinib is active against PDGFRa and most FIP1L1-PDGFRA-positive patients show dramatic responses to therapy. 5, 7, 8 In addition, a small proportion of CEL patients are positive for a variety of acquired platelet-derived growth factor receptor beta gene (PDGFRB) fusions that are also responsive to imatinib. [9] [10] [11] Identification of patients who are positive for PDGFR fusions is therefore critical to appropriate clinical management. However, some imatinib-responsive IHES patients are negative for known fusions, suggesting the presence of uncharacterized tyrosine kinase abnormalities in these cases. 5, 7 So far, PDGFRB fusions have only been identified in patients harboring visible chromosomal abnormalities of 5q31-33. FIP1L1-PDGFRA is cytogenetically cryptic but can be detected by fluorescence in situ hybridization (FISH) or reverse transcriptase-PCR. 5, 8 However, unambiguous detection of this fusion is complicated by the complex alternative splicing and diversity of genomic breakpoints in FIP1L1, low expression of the fusion gene in many cases and considerable variability in the proportion of cells involved in the malignant clone. 5, 12 To help address the shortcomings of current procedures to detect FIP1L1-PDGFRA and also to search for new PDGFRA fusion genes, we describe here an RT-PCR test to detect specific overexpression of the PDGFRA kinase domain. Application of this test to a cohort of patients led to the detection of a novel KIF5B-PDGFRA fusion as well as a case with FIP1L1-PDGFRA that had been missed by standard methods.
Materials and methods

Patients studied
A total of 270 cases with IHES or persistent unexplained eosinophilia were referred to the Wessex Regional Genetics Laboratory, Salisbury for routine molecular analysis between May 2002 and November 2005. Thirty-one cases (12%) tested positive for FIP1L1-PDGFRA by RT-PCR analysis and none were positive for BCR-ABL. The study group for the analysis described here comprised 12 FIP1L1-PDGFRA-positive cases and 217 FIP1L1-PDGFRA-negative cases.
PCR and reverse transcriptase-PCR
Peripheral blood or bone marrow leukocytes were lysed with guanidium thiocyanate and total RNA extracted using Qiagen RNeasy system (Qiagen, West Sussex) following the manufacturer's guidelines. The RNA was reverse transcribed into cDNA with random hexamers and tested for the presence of BCR-ABL, as described previously.
13 FIP1L1-PDGFRA was tested for by both single-step and nested RT-PCR using primers FIP1E6-F1 
PDGFRA multiplex
The PDGFRA RT-PCR multiplex was used to detect overexpression of the PDGFRA tyrosine kinase domain relative to the 5 0 part of the gene by employing a common PDGFRA reverse primer (PDA-exon15R 0 5 0 -GCTTTCATCAGCAGGGTTCAATC-3 0 ) and two forward primers that anneal to PDGFRA exons 10 and 13 (PDA-exon10F, 5-GATGCCTGGCTAAGAATCTCCT-3 0 and PDA-exon13F, 5
0 -CTGTCATGAAAGTTGCAGTGAAG-3 0 ). Amplifications were performed for 30 cycles with 661C annealing temperature using Invitrogen Taq polymerase (Invitrogen, Paisley, UK) with 0.1 mM PDA-exon10F, 0.2 mM PDA-exon13F and 0.4 mM PDA-exon15R 0 . As controls for FIP1L1-PDGFRA and normal PDGFRA expression, we used the cell lines Eol-1 and MG63, respectively. 6, 14 Bubble PCR Bubble PCR is a one-sided PCR technique designed to amplify unknown sequence adjacent to known sequence and has been used to amplify BCR-ABL genomic breakpoints. 15 The procedure was performed as described previously (digestion of peripheral blood-derived genomic DNA with HaeIII or RsaI and ligation to the duplex bubble oligonucleotide) with the following modifications: the ligated DNA was denatured for 5 min at 721C before removal of unligated bubble oligos using the QiaQuick PCR purification kit (Qiagen, West Sussex, UK). The PDGFRA intron 12-specific primer PDAI12-R3 was annealed to 1 ml of the ligated DNA and extended using Amplitaq Gold (Roche, Roche, Lewes, UK) to the end of the bubble oligo. Hotstart PCR (Amplitaq Gold, Roche) was performed (951C 15 min: 961C, 20 s; 661C, 50 s; 721C 50 s; for 30 cycles) to achieve amplification of this strand using the same PDGFRA primer and a forward primer, NVAMP-1 (5 0 -TGCTCGTAGTAATCGTTCGCAC-3 0 ), which is complementary to the newly synthesised unique sequence of the bubble oligo. A sample of 1 ml of this reaction was re-amplified using nested primers PDAI12-R4 and NVAMP-2 (5 0 -GTTCGCACGA-GAATCGCAAGAT-3 0 ). Rearranged bands were excised and gel purified (QiaQuick Gel Purification kit, Qiagen, Crawley, UK) and sequenced either directly or after subcloning into the TOPO PCR4 vector (Invitrogen, Paisley, UK).
Fluorescence in situ hybridization
Fluorescence in situ hybridization was performed using bacterial artificial chromosome (BAC) clones and chosen to flank PDGFRA and KIF5B (www.ensembl.org/index.html). Bacterial artificial chromosome DNA was grown, extracted and labelled by nick translation with alkali-stable digoxigenin or biotin-16-2 0 deoxy-uridine-5 0 -triphosphate (Roche, Germany) and hybridized as described previously. 16 In all experiments, 200 interphase cells were scored.
Case report for patient E683
Patient E683 was a 54-year old male who presented with fatigue, night sweats, weight loss and headaches. Blood counts showed a leukocytosis of 31 Â 10 9 /l with a marked eosinophilia of 26 Â 10 9 /l. The differential showed 6% neutrophils, 84% eosinophils, 0.5% basophils, 4% monocytes and 5.5% lymphocytes. Clinical examination showed a cardiac murmur but no thorax, abdomen or brain abnormalities. Parasitic investigations were carried out on stool samples but were found to be negative, as were blood tests for HIV 1 and 2 and TPHA. The bone marrow aspirate showed an increase of myeloid cells and marked eosinophilia, but an absence of blast cells. Immunophenotyping showed no abnormal B-or T-lymphocyte populations. Both BCR-ABL and FIP1L1-PDGFRA were negative by RT-PCR; however cytogenetics revealed eight out of 16 metaphases with a: 46XY, del(3)(p21),add(4)(q12),-10,13q?, þ der(?)(?-cen-?H4q12-4q28.3H10q11.2-10qter). The patient was initially treated with prednisone then hydroxyurea but no improvement was seen.
Results
Detection of PDGFRA kinase domain overexpression
The breakpoints within PDGFRA are very tightly clustered for both FIP1L1-PDGFRA and BCR-PDGFRA, and almost all mRNA fusions involve a truncated PDGFRA exon 12.
5,17 As a general screen for the presence of PDGFRA fusion genes, we designed a simple multiplex RT-PCR assay (Figure 1a ) to determine the relative expression of the PDGFRA kinase domain, which is retained in all fusions, compared to expression of the intact receptor, which is usually not detectable or weakly detectable by standard RT-PCR from peripheral blood or bone marrow leukocytes. We anticipated that samples with a PDGFRA fusion gene would overexpress the kinase domain relative to the normal receptor mRNA.
MG-63 cells express normal PDGFRA and, as expected, two bands of 650 and 290 bp (Figure 1b) are amplified. Although the lower band is stronger than the upper band, both are clearly visible. Eol-1 cells express FIP1L1-PDGFRA and only the smaller 290 bp band derived from the region retained in the fusion is visible. Most normal individuals do not show either of the PDGFRA mRNA-derived bands, but instead a 1049 bp genomic DNA fragment encompassing exons 13-15 is amplified (Figure 1b) . This band serves as a useful internal control for successful amplification.
Overexpression of PDGFRA in patient samples
Samples from 229 patients referred for IHES or persistent unexplained eosinophilia were analyzed by the PDGFRA 
Identification of PDGFRA rearrangements
Sufficient material was available for further analysis of seven of the nine cases found to overexpress the PDGFRA kinase domain. As all known breakpoints within PDGFRA are tightly clustered within or upstream of exon 12, we decided to investigate these cases by using bubble PCR from genomic DNA. We have previously used this technique to identify BCR-ABL breakpoints 15 and have found it to work very well for identifying FIP1L1-PDGFRA genomic fusions (J Score and NCP Cross, unpublished). The technique relies on the presence of a specific restriction site distal to the fusion point but within an easily amplifiable distance. We chose the two 4 bp cutters HaeIII and RsaI, which, in combination with primer PDAI12-R4, target genomic regions of 978 and 615 bp, respectively ( Figure 2a ). As these enzymes cut every 256 bp on average, products from the rearranged PDGFRA allele are generally expected to be smaller than the wild-type allele.
Rearrangements were detected for two of the seven cases with both restriction enzymes (Figure 2b ; data not shown). Unexpectedly, sequencing of the rearranged bands for one of the cases revealed FIP1L1 sequence. Reanalysis of patient cDNA confirmed the presence of FIP1L1-PDGFRA mRNA that had been missed on initial analysis. The fusion in this case was detectable by nested but not single-step RT-PCR.
Identification, confirmation and expression of the KIF5B-PDGFRA fusion gene
Sequencing of the rearranged allele from the second case (patient E683; Figure 2b ) identified a novel fusion between kinesin family member 5B (KIF5B; NM_004521) exon 23 and PDGFRA exon 12 ( Figure 3a) . To confirm the fusion, a 450 bp product was amplified from both patient peripheral blood and bone marrow genomic DNA but not from control DNA with breakpoint-specific primers KIF5B-exon22-F1 and PDAI12-R3 (Figure 3b) . A reciprocal genomic PDGFRA-KIF5B product was not detected with various primer combinations.
Expression of KIF5B-PDGFRA mRNA in peripheral blood and bone marrow was confirmed by the use of primers KIF5B-exon19F1 and PDA-exon14R1 in patient cDNA by single-step RT-PCR to yield the expected 702 bp product, but not in normal control cDNA (Figure 3b) . Sequencing of the cDNA product revealed exactly the same fusion junction as that seen in genomic DNA, that is, the translocation split KIF5B exon 23 and PDGFRA exon 12, and generated a hybrid exon. The fusion sequence is in-frame and is predicted to be translated into a 156 kDa chimeric protein of 1372 amino acids.
Confirmation of the KIF5B-PDGFRA fusion by fluorescence in situ hybridization
Subsequent to the finding of KIF5B-PDGFRA, the patient was found to have a complex karyotype with rearrangements involving chromosomes 3, 4, 10 and probably 13 (see above). To analyze the rearrangement in more detail, we performed interphase FISH analysis. Bacterial artificial chromosomes (Figure 4) . Unexpectedly, however, we did not observe a split signal with two BACs that flank PDGFRA (RP11-571I18 and RP11-24O10), suggesting that KIF5B had been inserted into the PDGFRA locus.
Patient response to imatinib
Following identification of the KIF5B-PDGFRA fusion, the patient was treated with 100 mg of imatinib per day after cessation of all other medication. Four days after the introduction of imatinib, total blood leukocytes returned to within normal parameters (3.5 Â 10 9 /l) with the disappearance of eosinophilia (0.105 Â 10 9 /l). A bone marrow aspirate was taken 6 months after the introduction of imatinib and all 25 metaphases analyzed had a normal karyotype. Furthermore, KIF5B-PDGFRA mRNA was undetectable by nested RT-PCR and also by nested genomic DNA PCR in peripheral blood specimens at 6 months and 1 year.
Discussion
Although several tyrosine kinase fusion genes have been implicated in the genesis of IHES/CEL, 2, 10, 11 by far the most common is FIP1L1-PDGFRA. This abnormality was originally described in more than half of IHES cases; 5 however, we have found here that the prevalence in a large (n ¼ 270) unselected series of patients is lower at 12%. This is similar to recent studies from the USA and France that found 11/81 (14%) and 6/35 (17%) of IHES cases to be FIP1L1-PDGFRA positive. 18, 19 To determine if other cryptic fusions involving PDGFRA might account for some of the remaining cases of IHES, we developed a simple RT-PCR screen to search for specific overexpression of the PDGFRA kinase domain relative to the normal intact receptor. This is straightforward for PDGFRA, as breakpoints within this gene are very tightly clustered and the normal receptor is expressed only very weakly in peripheral blood or bone marrow leukocytes. We found only nine cases (4% of cases analyzed) that apparently overexpressed the PDGFRA kinase domain, suggesting that novel fusions involving this gene are not a common cause of IHES. Fusion of KIF5B to PDGFRA in CEL J Score et al
We used bubble PCR analysis to identify genomic breakpoints in cases overexpressing PDGFRA. Unexpectedly, we found that one case had an FIP1L1-PDGFRA fusion, which had been missed on initial analysis. For reasons that are currently unclear, the expression of FIP1L1-PDGFRA is highly variable and only detectable by nested RT-PCR in many cases, including the case we missed initially. This is despite the fact that a majority of cells usually harbor the CHIC2 deletion. 5 Our findings suggest that occasional FIP1L1-PDGFRA-positive cases may be missed by standard techniques and therefore we now routinely perform the PDGFRA multiplex assay on all IHES cases, in addition to singlestep and nested RT-PCR for FIP1L1-PDGFRA.
Bubble PCR for five of the expression positive cases did not reveal any abnormalities. We find that bubble PCR is able to amplify genomic breakpoints from 490% of FIP1L1-PDGFRApositive patients (unpublished observations) and therefore we think it is unlikely that any of these cases had a PDGFRA fusion involving exon 12. It is possible that they have fusions that target other regions of PDGFRA or, alternatively, that they are simply false positives.
Of the remaining three expression positive cases, no further material was available for two, and the third yielded a novel KIF5B-PDGFRA fusion gene. KIF5B is the third PDGFRA partner gene to be identified after BCR and FIP1L1 and encodes kinesin family member 5b, a microtubule-based motor protein involved in transport of organelles. 20 The KIF5B protein is composed of three structural domains: an N-terminal region that hydrolyzes ATP and binds microtubules, a large central a-helical coiled-coil domain and a C-terminal domain that interacts with other proteins, vesicles and membranous organelles ( Figure 5 ). The KIF5B-PDGFRa chimeric fusion protein is predicted to contain most of the first two structural domains of KIF5B, including six of the seven coiled-coil domains and the entire kinase domain of PDGFRa (see Figure 5 ). By analogy with other tyrosine kinase fusion proteins, it is likely that one or more of these coiled-coil domains serve to dimerize and constitutively activate the fusion protein. 21, 22 The observed clinical, cytogenetic and molecular response of the KIF5B-PDGFRA patient to imatinib supports the notion that this fusion is the driving force behind the disease in this case.
In conclusion, we have shown that variant PDGFRA rearrangements are uncommon in IHES. However, screening for PDGFRA overexpression can help to identify cases that are positive for FIP1L1-PDGFRA or rare variant fusions. Fusion of KIF5B to PDGFRA in CEL J Score et al
